Exelixis Stock Hits Record High Amid Cancer Treatment Momentum
Investors are showing renewed interest in Exelixis (EXEL), with the stock hitting an all-time high on Wednesday. The surge comes as attention shifts from recent developments involving Moderna's cancer vaccine to promising momentum around Exelixis' oncology treatments. The breakout has positioned EXEL as a top pick for investors, highlighted by its rising relative strength line and strong performance in key technical levels. While the broader market remains cautious about near-term FDA decisions on certain therapies, Exelixis is gaining traction among traders seeking exposure to innovative cancer treatment options.
Topics: biotech cancer treatment investor behavior